AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 4th, 2020 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
This Amendment to License Agreement (this “Amendment”) is entered into as of May 1, 2020 (the “Amendment Date”), by and among Karyopharm Therapeutics Inc., a Delaware corporation (“Karyopharm”), and Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong (“Antengene”). Capitalized terms used herein and not defined herein shall have the meanings ascribed to them in the Agreement (as defined below).
